Allogeneic transplantation for high-risk chronic lymphocytic leukemia—a summary of a 16-year experience

In the pathway inhibitor era, the number of allogeneic stem cell transplantation (ASCT) for chronic lymphocytic leukemia (CLL) continues to decrease and this approach should be offered only after careful risk-benefit assessment. Nevertheless, ASCT still remains only curative therapeutic modality for...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Hematol
Main Authors: Helbig, Grzegorz, Spałek, Adrianna, Wieczorkiewicz-Kabut, Agata, Markiewicz, Mirosław, Kopera, Małgorzata, Zielińska, Patrycja, Woźniczka, Krzysztof, Kopińska, Anna, Grygoruk-Wiśniowska, Iwona, Koclęga, Anna
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6511342/
https://ncbi.nlm.nih.gov/pubmed/30919074
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-019-03679-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados